公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2016 | Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study | Yu K.-H.; Lai J.-H.; PING-NING HSU ; Chen D.-Y.; Chen C.-J.; Lin H.-Y. | Scandinavian Journal of Rheumatology | 34 | 29 | |
2008 | The significance of ANXA7 expression and its correlation with poor cellular differentiation and enhanced metastatic potential of gastric cancer | Hsu P.-I.; Huang M.-S.; Chen H.-C.; PING-NING HSU ; Lai T.-C.; Wang J.-L.; Lo G.-H.; Lai K.-H.; Tseng C.-J.; Hsiao M. | Journal of Surgical Oncology | 27 | 21 | |
2018 | Significant association of rheumatoid arthritis-related inflammatory markers with non-surgical periodontal therapy | Yang N.-Y.; CHEN-YING WANG ; Chyuan I.-T.; KING-JEAN WU ; YU-KANG TU ; Chang C.-W.; PING-NING HSU ; YEN-PING KUO ; YI-WEN CHEN | Journal of the Formosan Medical Association | 19 | 13 | |
2006 | Spinal pseudoarthrosis: a rare complication in psoriatic arthritis | KO-JEN LI ; CHIA-LI YU ; CHAO-YU HSU ; SONG-CHOU HSIEH ; PING-NING HSU | Journal of the Formosan Medical Association = Taiwan yi zhi | 2 | 1 | |
2012 | Spontaneous inflammatory pain model from a mouse line with N-ethyl-N-nitrosourea mutagenesis | Chen T.-C.; Wu J.J.-S.; Chang W.-P.; PING-NING HSU ; SUNG-TSANG HSIEH ; Shyu B.-C. | Journal of Biomedical Science | 6 | 6 | |
1991 | A subset of acute lymphoblastic leukemia with co-expression of myeloid antigens: prevalence and clinical significance. | PING-NING HSU ; HWEI-FANG TIEN ; Wang C.H.; Chen Y.C.; MING-CHING SHEN ; Lin D.T.; Lin K.H.; Liang D.C.; Lin K.S. | Journal of the Formosan Medical Association = Taiwan yi zhi | 5 | 0 | |
1995 | Superantigens: Gazing into the crystal ball | PING-NING HSU ; Huber B.T. | Current Biology | 5 | 4 | |
2022 | T Cell-Specific Deletion of TRAIL Receptor Reveals Its Critical Role for Regulating Pathologic T Cell Activation and Disease Induction in Experimental Autoimmune Encephalomyelitis | Chyuan, I-Tsu; Chu, Ching-Liang; Hsu, Chia-Lang; Pan, Meng-Hsun; Liao, Hsiu-Jung; Wu, Chien-Sheng; PING-NING HSU | Journal of immunology (Baltimore, Md. : 1950) | 1 | 0 | |
2022 | T Cell-Specific Deletion of TRAIL Receptor Reveals Its Critical Role for Regulating Pathologic T Cell Activation and Disease Induction in Experimental Autoimmune Encephalomyelitis | Chyuan, I-Tsu; CHING-LIANG CHU ; Hsu, Chia-Lang; Pan, Meng-Hsun; Liao, Hsiu-Jung; Wu, Chien-Sheng; PING-NING HSU | Journal of Immunology | 1 | | |
2021 | Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies | Chyuan, I-Tsu; CHING-LIANG CHU ; PING-NING HSU | Cancers | 25 | 25 | |
2023 | Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus | Hsu, Yu-Chen; CHIEN-HUNG CHEN ; HUI-FU HUANG ; Lee, Ying-Te; Wu, Meng-Chuan; Su, Chien-Wen; Chou, Huei-Chi; Wang, Li-Fang; Lee, Hsuan-Shu ; SHU-WHA LIN ; PING-NING HSU ; YAO-MING WU ; Sheu, Jin-Chuan; Weng, Meng-Tzu | Transplantation | 0 | 0 | |
2008 | TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells | MEN-LUH YEN ; Tsai H.-F; Wu Y.-Y; HSIAO-LIN HWA ; Lee B.-H; PING-NING HSU | Molecular Immunology | 37 | 37 | |
2013 | Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study | van der Heijde, Désirée; Tanaka, Yoshiya; Fleischmann, Roy; Keystone, Edward; Kremer, Joel; Zerbini, Cristiano; Cardiel, Mario H; Cohen, Stanley; Nash, Peter; Song, Yeong-Wook; Tegzová, Dana; Wyman, Bradley T; Gruben, David; Benda, Birgitta; Wallenstein, Gene; Krishnaswami, Sriram; Zwillich, Samuel H; Bradley, John D; Connell, Carol A; PING-NING HSU | Arthritis and rheumatism | 466 | 422 | |
2019 | Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four–Month, Phase III Study | van der Heijde D.; Strand V.; Tanaka Y.; Keystone E.; Kremer J.; Zerbini C.A.F.; Cardiel M.H.; Cohen S.; Nash P.; Song Y.-W.; Tegzová D.; Gruben D.; Wallenstein G.; Connell C.A.; Fleischmann R.; Hall S.; Nicholls D.; Rischmueller M.; Baker M.F.; Bessette L.; Cividino A.A.; Haraoui B.; Niall Jones H.; Keystone E.C.; Khraishi M.; Thorne J.; Birbara C.A.; Baraf H.S.B.; Bathon J.M.; Brodsky A.L.; Cush J.J.; Dikranian A.H.; Diri E.; Dura P.A.; Lohr K.M.; Fleischmann R.M.; Griffin R.M.; Halter D.G.; Hargrove J.K.; Bouda D.W.; Reddy Pasya S.K.; Hill G.L.; Jackson R.E.; Kafka S.P.; Kaine J.L.; Katzenstein P.L.; Kempf K.J.; Kolba K.S.; Kremer J.M.; Longley S.; Mathews S.D.; Milton A.C.; Misischia R.J.; Moorman H.A.; Moreland L.W.; Niemer M.W.; Palmer W.R.; Sayers M.E.; Schuette P.T.; Shamim T.; Shergy W.J.; Sikes D.H.; Silverfield J.C.; Siva C.; Taborn J.D.; Walsh B.T.; Wells A.F.; Wolfe S.M.; Adhikari P.; Amano K.; Bae S.-C.; Chandrashekara S.; Chopra A.K.; PING-NING HSU ; Iwahashi M.; Kadel J.K.; Kawabe Y.; Koh E.-M.; Lan J.-L.; Lee S.-K.; Lin H.-Y.; Liou L.-B.; Liu M.-F.; Migita K.; Miyamoto T.; Miyasaka N.; Mori S.; Munakata Y.; Ohta S.; Park W.; Park S.-H.; Rao U.R.; Shim S.C.; Shobha V.; Takasaki Y.; Takeuchi T.; Tanaka Y.; Tohma S.; Tsai W.-C.; Ueki Y.; Veeravalli S.C.M.; Wagh S.; Yamanaka H.; Yoo B.; Batalov A.; Bichoversuska D.; Dvorak Z.; Goranov I.; Hrytsenko H.M.; Kopackova J.; Mosterova Z.; Oparanov B.; Petrov A.; Pokrzywnicka-Gajek I.; Povoroznyuk V.V.; Rosa J.; Ruzga Z.; Settas L.; Stanislavchuk M.A.; Tseluyko V.I.; Vitek P.; de Freitas Zerbini C.A.; Brenol J.C.T.; Cardiel-Rios M.H.; Escalante W.J.O.; Maldonado-Lopez M.C.; Jaller Raad J.J.; Hernandez J.D.M.; Jauregui E.A.; Keiserman M.W.; Melazzi A.C.C.; Pascual-Ramos V.; Pinto L.T.; Radominski S.C.; Ximenes A.C.; de Morales S.V.; the ORAL Scan Investigators | Arthritis and Rheumatology | 68 | 59 | |
2019 | Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan | Chen D.-Y.; PING-NING HSU ; Tang C.-H.; Claxton L.; Valluri S.; Gerber R.A. | Journal of Medical Economics | 10 | 8 | |
2012 | TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces Osteoclast differentiation | MEN-LUH YEN ; PING-NING HSU ; Liao H.-J.; Lee B.-H.; Tsai H.-F. | PLoS ONE | 41 | 39 | |
2019 | TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment | Liao H.-J.; Tsai H.-F.; Wu C.-S.; Chyuan I.-T.; PING-NING HSU | Cell Death and Disease | 28 | 20 | |
2020 | TRAIL regulates T cell activation and suppresses inflammation in autoimmune diseases | Chyuan I.-T.; PING-NING HSU | Cellular and Molecular Immunology | 8 | 6 | |
2019 | TRAIL suppresses gut inflammation and inhibits colitogeic T-cell activation in experimental colitis via an apoptosis-independent pathway | Chyuan I.T.; Tsai H.F.; Wu C.S.; PING-NING HSU | Mucosal Immunology | 23 | 18 | |
2018 | TRAIL-mediated suppression of T cell receptor signaling inhibits T cell activation and inflammation in experimental autoimmune encephalomyelitis | Chyuan I.-T.; Tsai H.-F.; Wu C.-S.; Sung C.-C.; PING-NING HSU | Frontiers in Immunology | 31 | 30 | |